Evidence record · ER-TIRZEPATIDE-WEIGHT-013
Does authorised tirzepatide medicine produce weight loss?
Authorised tirzepatide medicine produces weight loss in eligible adults
Authorised tirzepatide medicine produces substantial weight loss in eligible adults when used with lifestyle support. Large randomised trials and the UK product authorisation support this claim. The finding belongs to the regulated medicine, population and monitoring pathway, not to unlicensed tirzepatide sold as a research product.
Claim boundary
What this verdict covers
The claim is limited to the authorised weight-management product and labelled adult population. It does not cover online powders, informal mixtures or products whose identity and strength have not been verified.
- Compound
- Tirzepatide
- Population
- Adults with obesity, or overweight with a related condition
- Outcome
- Percentage change in body weight
- Record ID
- ER-TIRZEPATIDE-WEIGHT-013
Evidence synthesis
What the research can support
SURMOUNT-1 randomised more than 2,500 adults and found substantially greater mean weight loss with tirzepatide than placebo over 72 weeks. The UK SmPC supplies the authorised indication and benefit-risk controls.
Why the confidence is high
Trial results are group averages and require the label’s contraindication, interaction and adverse-effect context. Longer-term comparisons and individual response remain separate questions.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-TIRZEPATIDE-WEIGHT-013 addresses one bounded question: Does authorised tirzepatide medicine produce weight loss?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Relevant human, the verdict is Supported and confidence is High. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| SURMOUNT-1 randomised trial | The trial found substantial weight loss with tirzepatide versus placebo. | It does not verify an unlicensed vial. | 10 August 2026 |
| Mounjaro UK Summary of Product Characteristics | The SmPC defines the authorised product, indication, warnings and use conditions. | It does not apply to differently made products. | 10 August 2026 |
| MHRA GLP-1 safety guidance | MHRA provides current safety and misuse advice for this medicine class. | It is not a personalised prescribing decision. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on Tirzepatide for this claim?
The verdict is supported for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
SURMOUNT-1 randomised more than 2,500 adults and found substantially greater mean weight loss with tirzepatide than placebo over 72 weeks. The UK SmPC supplies the authorised indication and benefit-risk controls. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is Tirzepatide authorised in the UK for this use?
Tirzepatide medicine is authorised in the UK for specific indications, presentations and populations. The authorisation does not extend to unlicensed powders or vials. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Tirzepatide is not listed as a prohibited substance on the 2026 WADA Prohibited List, but athletes must check current rules and medicine documentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What could change this verdict?
Material label changes, major head-to-head or long-term outcome evidence, or new regulator findings that alter benefit-risk for the authorised use. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation